Males and females differ in response to opioid agonist medications

Hendrée E. Jones; Heather Fitzgerald; Rolley E. Johnson

doi:10.1080/10550490590949569

Males and females differ in response to opioid agonist medications

Hendrée E. Jones, Heather Fitzgerald, Rolley E. Johnson

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.

Original language	English (US)
Pages (from-to)	223-233
Number of pages	11
Journal	American Journal on Addictions
Volume	14
Issue number	3
DOIs	https://doi.org/10.1080/10550490590949569
State	Published - May 2005
Externally published	Yes

ASJC Scopus subject areas

Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1080/10550490590949569

Cite this

@article{ac3698cafd004a9896dc6e6dd4d01413,

title = "Males and females differ in response to opioid agonist medications",

abstract = "Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.",

author = "Jones, {Hendr{\'e}e E.} and Heather Fitzgerald and Johnson, {Rolley E.}",

year = "2005",

month = may,

doi = "10.1080/10550490590949569",

language = "English (US)",

volume = "14",

pages = "223--233",

journal = "American Journal on Addictions",

issn = "1055-0496",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Males and females differ in response to opioid agonist medications

AU - Jones, Hendrée E.

AU - Fitzgerald, Heather

AU - Johnson, Rolley E.

PY - 2005/5

Y1 - 2005/5

N2 - Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.

AB - Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.

UR - http://www.scopus.com/inward/record.url?scp=22144493856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144493856&partnerID=8YFLogxK

U2 - 10.1080/10550490590949569

DO - 10.1080/10550490590949569

M3 - Article

C2 - 16019973

AN - SCOPUS:22144493856

SN - 1055-0496

VL - 14

SP - 223

EP - 233

JO - American Journal on Addictions

JF - American Journal on Addictions

IS - 3

ER -

Males and females differ in response to opioid agonist medications

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this